Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Regeneron, GlaxoSmithKline and Eli Lilly COVID-19 drugs prioritized for expedited review in Europe
Altimmune ditches COVID-19 nasal spray vaccine, halts therapeutic enrollment after trial setbacks
Moderna locks up Spikevax name in Europe, joins Pfizer's Comirnaty in wait for official brand approval in U.S.
UPDATED Coronavirus tracker: Half of parents concerned about rare heart conditions following adolescent vaccination
Roche and Atea's small, early data peek sees experimental COVID drug slash viral load in hospital patients
Hospitals' volumes, margins recovery still lags behind early 2019 numbers, Kaufman Hall says
Cambridge researchers pinpoint antimalarial, arthritis drugs for COVID-19 repurposing
COVID-19 tracker: Britain preps for boosters later this year; Switzerland gives 4M AZ doses to COVAX
Fujifilm's multibillion-dollar expansion spree rolls on with $850M capacity boost in U.S., U.K.

Featured Story

Regeneron, GlaxoSmithKline and Eli Lilly COVID-19 drugs prioritized for expedited review in Europe

By Kevin Dunleavy

The European Union has identified COVID-19 treatments from Eli Lilly, Regeneron, Celltron and GSK/Vir for priority review in its attempt expedite approvals. The bloc hopes to have three antibody drugs endorsed by October.

Altimmune ditches COVID-19 nasal spray vaccine, halts therapeutic enrollment after trial setbacks

By Kyle LaHucik

After not-so-promising results from a phase 1 trial, Altimmune is scrapping its COVID-19 vaccine nasal spray candidate and stopping further enrollment in a COVID-19 therapeutic program. The news comes just as the Delta variant picks up steam around the world.

Moderna locks up Spikevax name in Europe, joins Pfizer's Comirnaty in wait for official brand approval in U.S.

By Beth Snyder Bulik

Moderna has officially earned European Medicine Association approval for Spikevax as its COVID-19 vaccine brand name. Now, it joins Pfizer and BioNTech’s Comirnaty and AstraZeneca’s Vaxzevria, all with European name approvals, in awaiting a U.S. nod.

UPDATED Coronavirus tracker: Half of parents concerned about rare heart conditions following adolescent vaccination

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Roche and Atea's small, early data peek sees experimental COVID drug slash viral load in hospital patients

By Ben Adams

Infectious disease biotech and Fierce 15 winner Atea Pharmaceuticals alongside partner Roche have shown their antiviral can cut the viral load of SARS-CoV-02 in ill patients, though more data from a bigger trial will be needed to detail the level of success.

Hospitals' volumes, margins recovery still lags behind early 2019 numbers, Kaufman Hall says

By Dave Muoio

With improvements over a pandemic year to be expected, the consulting group advised a comparison against pre-pandemic financials as a better metric of hospitals' financial recovery.

Cambridge researchers pinpoint antimalarial, arthritis drugs for COVID-19 repurposing

By Angus Liu

By using computational analyses, scientists at the University of Cambridge have identified 200 approved drugs as possible candidates for repurposing against COVID-19 and validated two of them in early tests. Given that both drugs are well-established, they should be rapidly advanced into clinical trials to test whether they can prevent or treat the virus, the researchers proposed.

COVID-19 tracker: Britain preps for boosters later this year; Switzerland gives 4M AZ doses to COVAX

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Britain is preparing to administer booster shots to its most vulnerable citizens, such as the elderly, as early as this September, Reuters reports. Switzerland said it will give 4 million AstraZeneca doses it had reserved to the vaccine sharing program COVAX, although it will keep its mRNA shots. And more headlines.

Fujifilm's multibillion-dollar expansion spree rolls on with $850M capacity boost in U.S., U.K.

By Fraiser Kansteiner

Counting the latest investment, Fujifilm has blueprinted nearly $3 billion in manufacturing expansions since January, primarily in the U.S. The company will divvy up the latest $850 million infusion between operations in the U.K. and the U.S., where the company’s Texas and North Carolina plants are tackling manufacturing of Novavax’s late-stage pandemic vaccine, NVX-CoV2373.

COVID-19 Tracker